TP53 and neoplasm: This is consistent with studies indicating that Eμ-Myc lymphomas arise through acquisition of secondary or tertiary mutations that de-regulate tumour suppressor pathways such as those mediated by p19ARF and p53 that normally counteract the oncogenic effects of MYC.